

Non-Clinical Study of CD19 CAR-NK for Phase 1 Clinical Trial for Hematologic Malignancy



ONCOLOGY	
Preclinical	
Product Type	Cell therapies (Chimeric Antigen Receptor-NK, CAR-NK)
Indication	Hematologic Malignancy (B- cell lymphoma)
Target	CD19
MoA(Mechanism of Action)	<ul style="list-style-type: none">• CD19 CAR-NK cells are genetically engineered to express a chimeric antigen receptor (CAR) targeting CD19 on the surface of B cells.• CAR-mediated target recognition triggers direct cytotoxicity and cytokine-mediated cytotoxicity to eliminate tumor cells.
Competitiveness	<ul style="list-style-type: none">• CD19 CAR-NK is a fourth-generation CAR-NK that co-expresses a CAR signaling domain to maximize NK cell activation and IL-15, enhancing in vivo persistence and anti-cancer efficacy.• It is a highly purified CD19 CAR-NK (CD56+ CD19+ CD3- with over 90% purity), exhibiting low on-target/off-tumor toxicity and no CRS or neurotoxicity in normal tissues.• As an allogeneic cell therapy, it ensures cost competitiveness and supply stability through large-scale manufacturing technology for 'off-the-shelf' ready-to-use therapy with consistent quality.
Development Stage	Preclinical
Route of Administration	Intravenous infusion